Bo Angelin

Bo Angelin

Auto-generated profile, based on publicly available information

Bo Angelin

Cardio Metabolic Unit, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2010 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
PLPaul W. Ladenson
Paul W. Ladenson
JKJens D. Kristensen
Jens D. Kristensen
ERE. Chester Ridgway
E. Chester Ridgway
AOAnders G. Olsson
Anders G. Olsson
BCBo Carlsson
Bo Carlsson
BABo Angelin
Bo Angelin
Dyslipidemia increases the risk of atherosclerotic cardiovascular disease and is incompletely reversed by statin therapy alone in many patients. Thyroid hormone lowers levels of serum low-density lipoprotein (LDL) cholesterol and has other potentially favorable actions on lipoprotein metabolism. Consequently, thyromimetic drugs hold promise as lipid-lowering agents if adverse effects can be avoided.

1 December 2012 in Cell Metabolism
Verified
Journal Article
Closed access
BABo Angelin
Bo Angelin
TLTobias E. Larsson
Tobias E. Larsson
MRMats Rudling
Mats Rudling

1 April 2020 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
SSSara Straniero
Sara Straniero
ALAmit Laskar
Amit Laskar
CSChristina Savva
Christina Savva
JHJennifer H&Aumlrdfeldt
Jennifer H&Aumlrdfeldt
BABo Angelin
Bo Angelin
MRMats Rudling
Mats Rudling
Sara Straniero, Amit Laskar, Christina Savva, Jennifer Härdfeldt, Bo Angelin, Mats Rudling

1 December 2010 in Current Opinion in Lipidology
Verified
Journal Article
Closed access
BABo Angelin
Bo Angelin
MRMats Rudling
Mats Rudling
To summarize how thyroid hormones exert their effects on lipid metabolism through specific interaction with their nuclear receptors, to review studies of the effects of new and selective thyromimetic drugs in animals and humans and to identify important questions for future research. Thyroid hormones exert their effects by stimulation of thyroid hormone receptors that have different tissue distribution and metabolic targets. TRβ is predominant in liver and mainly responsible for effects on cholesterol and lipoprotein metabolism, whereas TRα is most important in fat, muscle, and heart. Thyroid hormone analogs (thyromimetics, tiromes) have been developed that activate TRβ and are selectively taken up and/or activated by the liver. Such compounds stimulate hepatic LDL receptors, cholesterol elimination as bile acids and cholesterol, and presumably promote reverse cholesterol transport. In animals, they retard atherosclerosis progression. In humans, eprotirome exerts favorable lipid-modulating effects while lacking thyroid hormone-related side-effects and maintaining normal hypothalamic–pituitary–thyroid feedback. When added to statins, it reduces LDL and non-HDL cholesterol, apolipoprotein B, and triglycerides as well as lipoprotein (a). Liver-specific and β-selective thyroid hormone analogs activate a spectrum of favorable thyroid hormone actions that optimize lipid metabolism and promote cholesterol elimination. Further studies should establish long-term safety and potential clinical usefulness of thyromimetics.

1 October 2018 in Gastroenterology
Verified
Journal Article
Open access
AAAmani Al-Khaifi
Amani Al-Khaifi
MRMats Rudling
Mats Rudling
BABo Angelin
Bo Angelin
Bile acid (BA) synthesis is regulated through suppression of hepatic cholesterol 7α-hydroxylase via farnesoid X receptor (FXR) activation in hepatocytes and/or enterocytes; in enterocytes, this process requires FGF19 signaling. To study these pathways, we quantified markers of BA synthesis (7α-hydroxy-4-cholesten-3-one [C4]) and cholesterol production (lathosterol), fibroblast growth factor (FGF)19, and BAs in serum from healthy male volunteers given 1 oral dose of the nonsteroidal FXR agonist Px-102 (0.15 mg/kg, 0.3 mg/kg, 0.6 mg/kg, 1.12 mg/kg, 2.25 mg/kg, 3.38 mg/kg, or 4.5 mg/kg). After 8 hours, serum levels of C4 decreased by 80% in volunteers given 0.15 mg/kg, whereas serum levels of FGF19 were unchanged. Serum levels of FGF19 increased significantly, in a dose-dependent manner, in volunteers given >0.3 mg/kg Px-102, up to as much as 1600%, whereas C4 levels remained significantly reduced (by >80%). For all doses, FGF19 levels returned to normal 24 hours after administration of Px-102. Serum levels of C4 decreased before levels of FGF19 levels increased, and were still reduced by 95% 24 hours after the highest dose (4.5 mg/kg) of Px-102, even though levels of FGF19 had returned to baseline. Our findings indicate that activation of hepatic FXR is able to suppress BA synthesis, independent of FGF19.

16 May 2014 in Journal of Internal Medicine
Verified
Journal Article
Closed access
PDF file
BABo Angelin
Bo Angelin
JKJens D. Kristensen
Jens D. Kristensen
MEMats Eriksson
Mats Eriksson
BCBo Carlsson
Bo Carlsson
IKIrwin Klein
Irwin Klein
PLPaul W. Ladenson
Paul W. Ladenson